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Test on existence of histology subtype-specific
prognostic signatures among early stage lung
adenocarcinoma and squamous cell carcinoma
patients using a Cox-model based filter
Suyan Tian1*, Chi Wang2 and Ming-Wen An3
Abstract
Background: Non-small cell lung cancer (NSCLC) is the predominant histological type of lung cancer, accounting
for up to 85% of cases. Disease stage is commonly used to determine adjuvant treatment eligibility of NSCLC patients,
however, it is an imprecise predictor of the prognosis of an individual patient. Currently, many researchers resort to
microarray technology for identifying relevant genetic prognostic markers, with particular attention on trimming or
extending a Cox regression model.
Adenocarcinoma (AC) and squamous cell carcinoma (SCC) are two major histology subtypes of NSCLC. It has been
demonstrated that fundamental differences exist in their underlying mechanisms, which motivated us to postulate the
existence of specific genes related to the prognosis of each histology subtype.
Results: In this article, we propose a simple filter feature selection algorithm with a Cox regression model as the base.
Applying this method to real-world microarray data identifies a histology-specific prognostic gene signature. Furthermore,
the resulting 32-gene (32/12 for AC/SCC) prognostic signature for early-stage AC and SCC samples has superior predictive
ability relative to two relevant prognostic signatures, and has comparable performance with signatures obtained
by applying two state-of-the art algorithms separately to AC and SCC samples.
Conclusions: Our proposal is conceptually simple, and straightforward to implement. Furthermore, it can be
easily adapted and applied to a range of other research settings.
Reviewers: This article was reviewed by Leonid Hanin (nominated by Dr. Lev Klebanov), Limsoon Wong and Jun Yu.
Keywords: Non-small cell lung cancer (NSCLC), Adenocarcinoma (AC), Squamous cell carcinoma (SCC), Cox model,
Prognosis, Histology-subtype specific, Gene expression barcode, Feature selection algorithm
Background
Non-small cell lung cancer (NSCLC) is the predominant
histological type of lung cancer, accounting for up to
85% of cases [1]. The overall five-year survival rate of
NSCLC is estimated extremely low at roughly 15% due
to late discovery of disease among more than two-thirds
of NSCLC patients, for whom surgical resection is no
longer an option [2]. Moreover, even among early stage
patients who have surgery, roughly 50% die of tumor
recurrence [3]. Clinical studies [4,5] have demonstrated
that adjuvant chemotherapy significantly improves the
survival of NSCLC patients at early stages. Disease stage
is commonly used to determine adjuvant treatment eligi-
bility, however, it is quite possible that a proportion of
stage I patients have poorer prognosis and may benefit
significantly from adjuvant chemotherapy while some
relatively good prognosis stage II patients may not benefit
significantly from adjuvant chemotherapies. Therefore,
identification of poor prognosis of early stage NSCLC
patients will assist in the prescription and administra-
tion of additional therapeutic interventions, which
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might potentially lead to better survival for the
patients with poor prognosis.
Microarray technology allows simultaneous monitoring
of thousands of genes and measuring of their expression
values. A major challenge in the analysis of data from
microarray experiments is high dimensionality, i.e. the
number of genes is much larger than the sample size.
However, with a feature selection algorithm, the original
set of genes can be reduced to a small gene subset that is
informative of the underlying differences among pheno-
types. A feature selection algorithm can be classified into
one of three categories – filter, embedded and wrapper –
depending on how the model fitting is combined with the
subset selection [6]. Details of these categories, including
relative merits and examples, are provided in a review by
Saeys et al. [6].
Many of the current approaches for identifying relevant
genes associated with survival phenotypes using microarray
data focus on trimming or extending a Cox regression
model [7], a commonly used model of analyzing survival
data in traditional clinical settings. For instance, Gui and Li
[8] proposed a novel feature selection algorithm called
LARS-cox, which uses the least angle regressions (LARS)
algorithm to obtain the solutions to a Cox model with an
L1 penalty. In an L1 penalty model, also referred to as the
least absolute shrinkage and selection operator (Lasso)
model, the objective function to be minimized is the nega-
tive log likelihood function plus the sum of the absolute
value of the coefficients, where the sum of the absolute
value of the coefficients is restricted to be less than some
constant s. Subsequently, Sohn et al. [9] applied the gradi-
ent lasso algorithm to a Cox model with an L1 penalty in-
stead and named the proposed method glcoxph. Compared
to LARS-cox, glcoxph claims to have prefect stability, save
computing time, and be more likely to achieve the global
optimum [9].
Adenocarcinoma (AC) and squamous cell carcinoma
(SCC), each approximately accounting for 40% of
NSCLC cases, are two major histology subtypes of
NSCLC. Fundamental differences have been found be-
tween the two subtypes in the underlying mechanisms
of tumor development, growth, and invasion [10,11].
Therefore, successful classification of NSCLC patients
into their corresponding subtypes is of clinical import-
ance. Many efforts [11-15] have been devoted to iden-
tifying subtype-specific genes, aiming at a precise
diagnosis of NSCLC subtype and a feasible guide for
personalized medicine. Many of those studies proposed
and adopted a novel feature selection algorithm. The
fundamental differences between AC and SCC of
NSCLC patients motivated us to speculate that specific
genes are related to survival rates for each histology
subtype. To the best of our knowledge, however, all
proposed Cox-model extensions ignore the histology
subtype information. Their primary objective is to
discriminate patients into subgroups with different
survival profiles based on gene expression data, that is,
selection of relevant gene subsets associated with prognosis
for the whole study population regardless of specific sub-
population characteristics.
In this article, we propose a simple feature selection
algorithm using a Cox regression model as the filter to
evaluate genes individually for potential subtype-
specific prognostic genes. Additionally, we explore the
use of expression barcode values [16,17], in which a
gene is deemed as either expressed or silenced based
on its actual expression values. The expression barcode
algorithm can detect a gene with nonlinear association
to the outcome. The novel features of the proposed
method are that it aims specifically at identifying
subtype-specific prognostic genes plus it is conceptu-
ally simple and straightforward to implement.
Methods and materials
Experimental data
The lung cancer microarray experiment was conducted by
[18] to assess the appropriation and accuracy of their previ-
ously identified 15-gene prognostic signature from another
independent NSCLC microarray experiment [19].
The data were deposited into the Gene Expression
Omnibus (GEO) repository under accession number
GSE50081. It was hybridized on Affymetrix HGU133 Plus
2.0 chips. In this cohort, there were 181 early-stage NSCLC
patients who did not receive any adjuvant therapy. Because
we were only interested in AC and SCC subtypes, we ex-
cluded those samples with ambiguous histologic subtype
labels and those other than AC and SCC, resulting in
127 AC and 42 SCC samples.
Pre-processing procedures
Raw Affymetrix data (CEL files) were downloaded from
the GEO repository and expression values were obtained
using the GCRMA [20] algorithm. Data normalization
across samples was carried out using quantile
normalization and the resulting expression values were
log2 transformed.
First, only probe sets that demonstrated a certain degree
of variation across samples were selected. Specifically,
probe sets with standard deviation (SD) below 0.1 were
regarded as non-informative and eliminated. Then
moderated t-tests using limma [21] were conducted to
identify the differentially expressed genes (DEGs) be-
tween SCC and AC. Exclusion of those non-DEGs was
the second stage of the filtering, and the cutoff for the
false discovery rate (FDR) was set at 0.05. There were
5,465 down- and 5,484 up-regulated probe sets, corre-
sponding to 6,202 unique DEGs. To deal with multiple
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probe sets matched to one specific gene, the one with
the largest fold change was kept.
When using the barcoded values, the probe sets that
expressed at extremely high (>95% in AC and >90% in
SCC) or low frequencies (<5% in AC and <10% in SCC)
were eliminated. This additional filtering was necessary
to avoid problems associated with complete separation –
where one specific gene is expressed in all samples of
one subtype and silenced in the other. We used different
cutoffs for AC and SCC mainly because the number of
SCC samples is only one-third that of AC samples. The
resulting 2,207 probe sets corresponding to 1,889 unique
DEGs were fed into the downstream analysis.
Methods
The Cox proportional model to identify subtype-survival
relevant genes
To identify genes informative of survival rate for AC/
SCC histology subtypes, a Cox model was fit on each
gene. Specifically, for patient i (i = 1,…,Nj) of subtype j
(j = 0,1 representing AC and SCC, respectively), tij, δij,
Xij1,…,Xijp are observed. Here, δij is the censoring indica-
tor equalling 1 if this patient is dead and 0 otherwise, tij
denotes survival time if δij = 1 and censoring time other-
wise, and Xij = (Xij1,…,Xijp)
T represent actual expression
values or barcoded expression values for the p genes
under consideration. Then the hazard function of patient
i for gene g (g = 1,…,p) is given by,
λijg tð Þ ¼ λ0g tð Þexp β1g I j ¼ 1ð Þ þ β2gXijg þ β3g I j ¼ 1ð Þ  Xijg
 
ð1Þ
where λ0g(t) is an unknown baseline hazard function,
and I(j = 1) is an indicator for the histology subtype of
patient i belonging to SCC. Here β2g and β3g are the pa-
rameters of interest, with β2g representing the change in
log hazard rate associated with 1-unit increase in the ac-
tual expression value of gene g among AC and β3g repre-
senting the additional change in log hazard rate
associated with the SCC subtype. Of particular interest
is when there is no overlap between subtype-specific
prognostic genes. These genes can be identified as those
that have either β2g or β2g + β3g, but not both, being sta-
tistically significantly different from zero. Figure 1 illus-
trates all possible scenarios.
It is worth mentioning that both λ0g and β1g are gene-
specific, meaning the subscript g in these two terms can-
not be dropped. Here, λ0g takes into account the influence
of relevant genes other than gene g and clinical covariates
on the hazard rate. β1g may assess the imbalance among
Figure 1 Scenarios of the Cox-model filter and their interpretation. β2 and β3 are the coefficients for the gene term and gene × subtype
interaction term in Equation 1, and they are the parameters of interest. Ideally, non-overlap of genes fitting case B and those fitting case E
suggests existence of mutually exclusive subtype-specific prognostic genes. Character A-G represent different situations (or cases) for the
proposed model.
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those factors in AC versus SCC subtypes; its theoretical
value is zero. We used the Benjamini and Hochberg
procedure [22] to correct for multiple comparisons.
Barcode algorithm
In the barcode algorithm by McCall et al. [17], the
expressed genes are coded with 1’s and the silenced
genes are coded with 0’s. Briefly, McCall et al. [17] used
a mixture model to fit the silenced and expressed distri-
bution of observed log2 transformed intensity values for
each gene. The mixture model is as follows,
yig jμg e 1−pg  N μg;τ2g þ pg  U μg ; Sg 
μg eN ξ; λ2 
τ2g e IG α; βð Þ
where yig is the observed log2 intensity for gene g in sample
i, and is assumed to follow a normal distribution of N(μg,
τg
2 ) if the gth gene is silenced or a uniform distribution of
U(μg, Sg) if the gth gene is expressed. Here, μg denotes the
mean of silenced genes and Sg denotes the saturation value.
Then, silenced means and variances for each gene are as-
sumed to follow normal and inverse gamma distributions,
respectively. By introducing a hierarchical model structure,
and in particular the higher-level parameters, i.e., α, β, ξ,
and λ, more stable estimates of τg
2 can be obtained because
information can be borrowed and shared across genes,
leading to a shrinkage of individual estimates toward the
overall average.
To determine whether a gene is more likely to be si-
lenced or expressed, the standardized intensity value
(yig − μg)/τg was calculated. Using a fixed threshold
value C, the expression barcode for a gene, a vector of
1’s and 0’s (indicating expressed and silenced) is de-
fined as,
big ¼ 1 Φ − yig−μg
 
=τg
 
< C
0 otherwise
(
where Φ is the cumulative density function of a standard
normal. Parameter estimation in this hierarchical model
is done using a modified EM algorithm; details are avail-
able in the supplementary material of [17].
Statistical language and packages
All statistical analysis was carried out in the R language
version 3.0 (www.r-project.org), and packages such as frma
(for barcode) and gcrma were from the Bioconductor
project (www.bioconductor.org).
Results and discussion
Real data
As mentioned in the Background section, our goal is
to identify histology subtype-specific prognostic genes.
Such signatures may guide the prescription of adjuvant
therapies to eligible patients and avoid therapies to patients
with good prognosis. To test this research hypothesis, we
applied the filter feature selection method introduced in
the Methods section, which is hereafter referred to as the
Cox-model filter. Figure 2 highlights the study schema. As
expected, the Cox-model filter identified some subtype-
specific prognostic genes.
Feature selection using Cox models
We fit the Cox model in Equation (1) and estimated the
parameters of interest for each of 6,202 genes under
consideration. We examined Schoenfeld residuals for all
models to test the proportional hazards assumption of a
Cox model. The p-values for those tests ranged from
0.0037 to 0.9995; with 48 values being less than 0.05 and
5 less than 0.01. These numbers are much less than 5%
and 1% of the total number of genes. Furthermore, there
was no overlap between the genes that were identified as
prognostic and those with p-values less than 0.05 in the
test for proportionality. These suggest the proportional
hazards assumption is plausible.
Based on the actual expression values without extra
barcode frequency filtering, there were 19 and 24 genes
whose coefficients were statistically significantly different
from zero for AC and SCC subtypes, respectively. With
extra barcode frequency filtering, there were 32 genes
and 12 genes with AC and SCC coefficients statistically
significantly different from zero using the actual expres-
sion values while there were 26 genes and 0 gene re-
spectively using the barcode expression values. Venn-
diagrams were made to show how these three selected
gene sets intersected (Figure 3).
Based on the actual expression values, we justified the
existence of histology subtype-specific prognostic genes;
whereas based on the barcode expression values, we
identified 26 AC-specific and no SCC-specific genes. We
observed, however, that the number of prognostic genes
for early-stage NSCLC tends to be larger when using the
actual expression values versus the barcoded values. One
possible explanation was that after the actual expression
values were dichotomized into barcoded values, the
genes with weak or even moderate association to sur-
vival were discarded.
Additionally, we conducted a sensitivity analysis to ex-
plore the effects of different cutoffs (i.e., cutoffs for moder-
ated t-test filtering, barcode frequency filtering, and FDR of
the Cox models) on the results. First, we evaluated the per-
formance of the resulting signatures in terms of classifica-
tion accuracy (i.e., the rate of correctly classifying samples
into their survival profiles) and the area under ROC curve
(AUC) statistics using different FDR cutoffs values (Figure 4)
in both moderated t-test filtering and the Cox-model filter.
For both steps, we identified 0.05 as an optimal value
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Figure 2 Study schema showing how the 29-, 32-, and 26-gene signatures were obtained. The 29-gene signature was obtained using all
DEG genes; the 32-gene signature was obtained using 1889 genes with extra barcode-frequency filtering and actual expression values of these
genes; and the 26-gene signature was obtained using the barcode values of those 1889 genes. We used both PCA procedure and the models
with all genes as covariates to compute the risk scores and found out that even the proportion in variance of variables is higher than 95% by the
selected PCs, the performance is inferior than that using all selected genes as covariates.
Figure 3 Venn-diagram showing how the 29-, 32-, and 26-gene signatures intersect.
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because it achieves the optimal combination of perform-
ance and model parsimony. Moreover, we found out the
conclusions are consistent across different cutoffs for bar-
code filtering (i.e., 5% for AC and 10% for SCC, 10% for AC
and 10% for SCC, 10% for AC and 20% for SCC, and 20%
for AC and 20% for SCC).
Risk score construction
Given the number of selected genes is still large relative
to the sample size, to avoid potential fitting problems
arising from a regression model including all selected
genes as covariates we also adopt the procedure in [19]
to construct a risk score for each sample. This procedure
consists of two steps. First, a principal component ana-
lysis (PCA) is conducted and the first four principal
components (PCs) are recorded. Then a multiple Cox
regression model is fit with the first four PCs as
covariates, and the risk scores are calculated using the
coefficients of these four PCs in the Cox model as
weights. We modified the procedure by determining the
number of PCs based on when the proportion of vari-
ance in the selected genes explained by the PCs exceeds
95%. Moreover, since PCA only applies for continuous
variables, we used the actual expression values for the
26 AC-specific genes identified using barcode values to
construct the risk scores.
Using the mean value of those risk scores as a cutoff,
we classified patients into a low-risk group or a high-
risk group. Overall, the results from the PCA method is
inferior to that using all genes as covariates even though
the explained proportion of variances by those PCs ex-
ceeds 95%. We obtained Kaplan-Meier curves using the
resulting risk scores (Figure 5), and compared the two
curves using log-rank tests (Table 1).
Figure 4 Sensitivity curves for different cutoffs in the Cox-model filter. A) Predictive statistics as a function of different FDR cutoff in
moderated-t test filtering; B) Predictive statistics as a function of different FDR cutoff in Cox-model filter, using 6,202 genes. Here, No.1/No.2/No.3
represent the overall/AC/SCC size of selected gene sets, respectively; the number in the following line represents the total genes under consideration in
Panel A; accuracy stands for the proportion of rightly classified patients; risk scores were constructed using PCA method since the number of selected
genes is bigger than the number of samples for most values in Panel B. From these two plots, we observed that 0.05 is an optimal threshold in both
steps based on the model parsimony and predictive performance.
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Comparison with relevant prognostic signatures
Although clinical-pathological staging is the current
standard for determining NSCLC prognosis, a number
of gene expression signatures have been reported to have
better performance on predicting survival of NSCLC pa-
tients. Shao et al. [23] provides a comprehensive review
on those prognostic gene expression signatures.
Both the 29 (19 AC/24 SCC specific)-gene and 32
(32 AC/12 SCC)-gene signatures outperformed the most
relevant 15-gene signature, suggesting that using subtype-
specific genes can improve the prediction of one patient’s
prognostic status (Table 1). Moreover, these two signatures
showed substantial superiority over the 13-gene signature
proposed by Guo et al. [24]. Despite these promising re-
sults, additional evaluation of these signatures on an inde-
pendent dataset is warranted since they were trained and
tested on the same data set.
Unsurprisingly, there is almost no overlap of genes be-
tween our signatures and other relevant ones. In fact, in-
consistency among gene expression signatures developed
even on the same data is very common [25,26]. This
may be due to the noisy nature of microarray data, the
relatively small sample size of a microarray study, and
different preprocessing and downstream statistical
Figure 5 Kaplan-Meier curves between high-risk and low-risk groups using 32-, 15-, 13-gene prognostic signatures with selected genes
as covariates in risk score construction. Patients were stratified into high-risk and low-risk groups for death on the basis of their risk scores.
The cutoff was set at the mean value of those risk scores. Log-rank tests were used to compare the survival profiles of the high-risk and low-risk
groups. All p-values of those tests were <0.05.
Table 1 The performance of different prognostic signatures
Signature (# AC/# SCC) # Low /high risk # of PCs/ % of variance for AC, SCC Accuracy (%) All (AC/SCC) AUC (%) (AC/SCC) p-value
(log rank)
A: Using all covariates in the cox model for risk score construction
29-gene (19/24) 91/78 – 72.19(73.23/69.05) 83.17/79.29 1.74 × 10-9
32-gene (32/12) 87/82 – 74.56(76.38/69.05) 79.82/79.57 2.74 × 10-13
26-gene (26/0) a1 83/86 – 62.72 69.96 1.22 × 10-4
26-gene (26/0) b1 88/81 – 63.31 73.90 9.01 × 10-5
15-gene by Zhu2 90/79 – 63.31 68.99 1.43 × 10-4
13-gene by Guo2 84/85 – 63.31 67.55 4.51 × 10-4
B: Using the modified PCA procedure for risk score construction
29-gene (19/24) 86/83 3/96.19, 4/95.75 68.05(70.87/53.19) 76.72/68.26 3.34 × 10-7
32-gene (32/12) 86/83 12/95.75, 7/96.63 65.68(66.93/61.90) 77.18/71.89 2.26 × 10-5
26-gene (26/0) a1 81/88 16/95.76 60.36 66.59 1.22 × 10-3
15-gene2 91/78 3/96.41 60.36 64.04 1.34 × 10-3
13-gene2 91/78 2/96.71 60.36 58.20 1.34 × 10-3
Note: 29-gene signature was obtained using all 6,202 genes under consideration; 32-gene signature was obtained using 1,889 genes with extra barcode-frequency
filtering and actual expression values of these genes; 26-gene signature was obtained using the barcode values of those 1,889 genes; 15-gene signature was the
one in Zhu’s study [19]; 13-gene signature was the one in Guo’s study [24].
1Those statistics were computed for all samples pretending AC-specific genes are common prognostic genes for both AC and SCC; a: abbreviates for actual values
and b: abbreviates for barcoded values. 2Those are AC/SCC common genes.
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methods used to define a signature. It is common prac-
tice then to examine the underlying pathways of selected
genes to identify possibly shared pathways working to-
gether towards a biological effect [27]. Pathway analysis
using STRING [28] for the 32-gene, 15-gene and 13-
gene signatures is presented in Additional file 1, and the
constructed functional protein-protein networks for
these three signatures using STRING are presented in
Additional file 2.
Applying the Cox-model filter to an RNA-seq data
Because microarray technology has many weaknesses,
we applied the procedure to an RNA-seq data set with
489 AC and 488 SCC samples downloaded from The
Cancer Genome Atlas (https://tcga-data.nci.nih.gov/tcga/),
dated August 13, 2014. Our primary objective is further
testing of the existence of subtype-specific prognostic
markers using data from a more advanced sequencing
technology. Counts-per-million (CPM) values were calcu-
lated and log2 transformed by the voom function [29] in
the limma package. Only those patients without adjuvant
treatments and in early tumor stages (i.e., stage I and II)
were included in analysis. These criteria excluded almost
85% of patients, leaving 62 SCC and 81 AC patients for the
downstream analysis. Since the barcode algorithm does not
apply to the RNA-seq technology, only the analysis using
the actual expression values was conducted. None of the
β2s and β3s in the Cox models was statistically significantly
different from zero. 3,882 DEGs were identified using cut-
off values of 0.05 and 2.0 for FDR and fold change, respect-
ively. The Cox model-based filter algorithm was applied to
these DEGs again, and no genes were identified as statisti-
cally significant. To assess the sensitivity of the FDR
threshold in the cox models, we also used more liberal
values (0.1. 0.15, 0.2, 0.25, 0.3). However, the conclusions
did not change.
More interestingly, we included normal controls in
order to identify potential prognostic genes with altered
expression relative to the original normal expression vari-
ability. Using those patients having paired controls, we
took the difference of log2(CPM) values between tumor
and matched normal samples for each gene. The resulting
differences instead of the actual log2(CPM) values were
used in the Cox models. Notably, we relaxed the require-
ment of early histology stages and adjuvant treatment
naïve in this analysis because of the limited number of pa-
tients with paired controls. Based on the DEG’s and using
an FDR cutoff of 0.3, there were 5 and 17 genes with β2g
and β2g + β3g being statistically significantly different from
zero respectively. Based on all genes and using an FDR
cutoff of 0.25, there were 33 and 79 such genes. In
summary, including normal controls might be helpful for
identifying the subtype-specific prognostic genes. Further
investigation is warranted. Nevertheless, our focus in this
article is not on such genes. Given the fact that it is not
common practice in the clinical setting to have normal
controls, we believe a direct comparison between SCC
and AC subtypes is of practical importance.
Comparison with other algorithms and further validation
using the RNA-seq data
Here, we selected 32-gene signature obtained using ac-
tual values of 1,889 genes as the final model. First, we
evaluate the goodness-of-fit of this model. Based on the
likelihood ratio test, 32(32 AC/12 SCC)-gene models
were significantly better than null models (p = 0.0002/
0.0369 for AC/SCC, respectively). The 32-gene signature
is listed in Table 2.
Second, we evaluate the adjusted prognostic capacity
of this signature after controlling for other clinical
pathological factors (including gender, age, stage, and
smoking status). By fitting an extra Cox-regression
model with the constructed risk score from the prognos-
tic gene signature and those clinical factors as covariates
for each subtype, we found that the models including extra
clinical factors are not statistically better than the models
without them (p = 0.3126/0.0536 for AC/SCC). We inter-
pret this finding with caution because for the SCC subtype,
the p-value is only slightly larger than 0.05.
Finally, in order to further evaluate the proposed Cox-
model filter, we compared its performance with two state-
of-the art algorithms, glcoxph and Coxpath [30]. Two R
packages glcoxph and glmpath are used for glcoxph and
Coxpath analysis, respectively. Here, we applied both algo-
rithms separately to SCC and AC samples to identify
subtype-specific genes. The results (Table 3) indicate that
the Cox-model filter performs comparably with these two
algorithms when either testing on microarray data itself or
validating on the independent RNA-seq data.
Synthesized data
To explore the characteristics of our proposed proced-
ure, we used the actual expression values for 1,889 genes
after barcode filtering to conduct a simulation study.
Specifically, we randomly selected 4 genes –CERCAM,
ITGA5, MTHFD1L, and PLOD1 – to be prognostic
markers. The expression values of these 4 genes were
represented by X1 ~ X4, respectively.
Extreme case 1: mutually exclusive markers for
each subtype. In this case, AC and SCC have completely
distinct sets of markers. The hazard functions are speci-
fied as follows,
λSCC ¼ λ0exp 1:42X1− 0:75X2ð Þ
λAC ¼ λ0exp 0:225X3 þ 0:177X4ð Þ
among the remaining genes, we randomly selected 96
in order to have a total of 100 features under
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consideration. Thus, all but the first four genes are ran-
dom noise. The survival time for each patient was simu-
lated via a Cox-exponential distribution [31], and the
censoring rate was fixed at 30%.
Extreme case 2: no subtype specific prognostic
genes. In this case, we assume AC and SCC share iden-
tical prognostic markers,
λAC&SCC ¼ λ0 exp 1:42X1− 0:75X2 þ 0:75X3 − 0:59X4ð Þ
for each case, we simulated 500 datasets and applied
our proposed method to them.
Simulation results
In Extreme case 1, β2s for genes 3 and 4, and (β2 + β3)s for
genes 1 and 2 are expected to have non-zero coefficients.
However, the AC-specific genes (i.e., genes 3 and 4) tend to
be identified as the common prognostic markers for both
subtypes (Table 4A). This unexpected finding could be due
to the correlations among the four genes.
Varying the coefficients for genes 1 and 2, we found
that when the signals are weak or moderate for the SCC
subtype, the corresponding coefficients of (β2 + β3)s for
genes 1 and 2 tend to be zero (data not shown). This im-
plies that unless the signals are strong, as for gene 1 with
a coefficient of 1.42 in the first simulation, the proposed
procedure is highly likely to miss the SCC-specific prog-
nostic markers. Again, one explanation is the correlation
structure among genes.
In Extreme case 2, we found both β2 and β2 + β3 were
non-zero for genes 1-4 in all 500 simulated data, as ex-
pected (Table 4B). Overall, when using the barcoded
values, the total number of selected genes is substantially
less than when using the actual values. Moreover, the
false positive rate as indicated by the average number of
selected genes is high. This may be due to the fact that
our method cannot filter out (irrelevant) genes that are
highly correlated with relevant ones. Additional care is
needed to eliminate these false positives. For example,
the pathway information may be used as a priori to dis-
tinguish between relevant and irrelevant markers.
To explore if the imbalance size between the two sub-
types and the complicated correlation structure among
genes influence the performance of the Cox-model filter,
we conducted extra simulations. For those simulations,
we used independent normally distributed random vari-
ables. The results, presented in Additional file 1, justify
our two assertions. Specifically, if the sample size of a
subtype is substantially smaller, then its corresponding
subtype-specific genes are likely to be missed unless
their effect is adequately large. Second, the inferiority of
modeling parsimony in the Cox-model filter is due to it
cannot eliminate those (irrelevant) genes highly corre-
lated with relevant ones.
Conclusions
Given the fundamental differences in the underlying
mechanisms of tumor development, growth, and invasion
between AC and SCC of NSCLC patients, we hypothesized
that there exist histology subtype-specific genes relevant to
prognosis of patients. As expected, some subtype-specific
genes do emerge when we applied the proposed feature se-
lection method to real-world microarray data.
Nevertheless, the study itself has several limitations.
First, only a single microarray experiment was consid-
ered. Moreover, the number of AC samples is three
times that of SCC samples, causing an imbalance
Table 2 32-gene signature
Gene βAC βSCC
CCRN4L 0.1107
MYBL2 0.2637
FOXM1 0.1565
WRB -0.2001 0.8382
RCAN2 -0.2258 0.417
TMEM243 0.8313 -1.0549
GTSE1 -0.4777
TOX -0.5018 0.1849
RAPGEF5 0.0773 -0.4773
ABCA8 0.095 -0.2682
BMP1 0.227
KCNS3 0.195 -0.193
FST 0.2765
CHRDL1 -0.1046
TPX2 0.2824
CTSV 0.4525
PREPL -0.386 -0.3739
LMBRD1 0.3392 -1.1411
PID1 -0.323 -0.5716
ZBED2 0.1738
NUSAP1 -0.0237
GINS2 0.3008
ALDH6A1 -0.4107
KIF18B -0.5523
CERCAM 0.0772
PDPK1 -0.746 0.9029
CMIP 0.2109
PARM1 -0.0172 0.1751
BRD4 0.778
CDT1 -0.2528
SLC38A7 -0.0758
SHE 0.3078
Note: 32-gene signature was obtained using 1,889 genes with extra barcode-
frequency filtering and actual expression values of these genes.
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between the two subtypes. A larger data set that inte-
grates many relevant microarray experiments is desired
because the results based on such an integrated data set
might be more statistically powerful and generalizable to
a broader population. Of course, the issue of batch ef-
fects when combining data from multiple microarray
experiments conducted in different laboratories must be
considered carefully. A highly desirable feature that such
big datasets should possess is to include gene expression
profiles from normal controls.
Second, microarray technology suffers from being in-
sensitive to detecting genes with low expression values,
i.e., 1 to 10 copies per cell. Thus, we applied the proposed
procedure to an RNA-seq data, given that RNA-seq tech-
nology has perfect precision and sensitivity to detect low-
expressed genes. However, we did not identify any prog-
nostic signatures most likely because the study population
in the RNA-seq data is not homogenous as it is with
microarray data and those patients have not been followed
up for an adequate period.
Third, the proposed filter feature selection method can-
not evaluate additive effect of genes. Thus genes with large
coordinated effect but small individual effects on prognosis
are highly likely to be missed. We are currently working on
a new approach that uses the corresponding partial likeli-
hood and an embedded feature selection algorithm to sim-
ultaneously select relevant genes and estimate risk scores.
Using the integrated data from multiple experiments and
this embedded feature selection method, we will revisit this
hypothesis of the existence of histology-specific prognostic
gene signatures.
Finally, the proposed method is an individual-gene-based
method, which ignores the biological information from the
corresponding functional networks of those genes. Such in-
formation is useful for gleaning insight on identification of
true genetic markers associated with phenotype of interest.
These questions of how to further stratify based on func-
tional relevance or to incorporate biological information as
a priori information for feature selection will be important
to consider in our future work.
Table 4 The simulation results
Actual value (frequency %) Barcoded value (frequency %)
AC (β2) SCC (β2 + β3) AC SCC
A. Simulation 1: a case of mutually exclusive markers for each subtype
Gene1 0 100 0 100
Gene2 0 100 0 52.8
Gene3 100 99.6 97.4 46.2
Gene4 90.6 100 97.8 100
Ave.# of selected genes 18.53 17.82 10.00 9.98
B. Simulation 2: a case of no subtype specific prognostic genes
Gene1 100 100 100 99.8
Gene2 100 100 100 100
Gene3 100 100 100 100
Gene4 100 100 100 100
Ave.# of selected genes 33.57 29.88 27.28 19.26
Note: Frequency represents the percentage of being non-zeros among 500 replicates; Actual value represents the analysis conducted using the actual gene
expression values; barcoded value represents the analysis conducted using the barcode expression values.
Table 3 Comparison with other algorithms
Algorithm # of genes (AC/SCC) Accuracy AUC p-value
A: Comparison with other algorithms on the microarray data itself
Cox-model filter 32(32/12) 74.56(76.38/69.05) 79.82/79.57 2.74 × 10-13
Coxpath separate 142(108/40) 81.66(83.47/76.19) 90.95/87.85 0
glcoxph separate 11(1/10) 66.27(60.63/83.33) 69.99/91.42 3.91 × 10-2
B: Further validation those signatures on the RNA-seq data
Cox-model filter 30(30/11)1 56.8(52.86/61.82) 52.19/68.14 0.305
Coxpath separate 126(97/32)1 52(50/54.56) 47.29/67.36 0.272
glcoxph separate 9(1/8)1 55.20(51.43/60) 57.21/56.31 6.86 × 10-2
Note: In this comparison, we used 1,889 genes with extra barcode-frequency filtering and their actual expression values. 1There are some genes missing from the
resultant signatures since the RNA-seq data is on a different platform from microarray data.
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Despite these limitations, our proposed method
nevertheless has its merits. It is conceptually simple
and straightforward to implement. Furthermore, it
saves on computing time because it does not require
optimization of tuning parameters via cross-validation.
Therefore, we expect that researchers, especially those
with minimal statistical knowledge and experience, can
readily adapt this method in their own research settings.
Reviewers’ comments
Reviewer number: 1 Dr. Leonid Hanin, Idaho State
University, United States of America
The article represents a hodgepodge of references to
various methods and results related to the analysis of
microarray gene expression data and prognostic gen-
omic signatures of cancer. The methodology is dubi-
ous, and its relevance to the problem at hand has not
been adequately justified. Statistical analysis in the article
depends on numerous, and partly untestable, prior as-
sumptions that were not even mentioned. The all-
important computational details were not provided, and I
have little confidence that computations were carried out
correctly, whatever “correctly” means. Selection of
methods, parametric families of distributions and cut-offs
is arbitrary and is not accompanied by any discussion or
sensitivity analysis. The exposition is extremely sloppy, and
many sentences seem to be just meaningless combinations
of various pieces of terminology.
In my opinion, the article represents a pointless fishing
expedition with inadequate net. I have a strong feeling
that the article falls into the “junk science” category, and
I believe its publication would be an embarrassment to
the journal.
Authors’ response: We feel our manuscript might have
been misinterpreted. In order to fix this, we have edited this
manuscript sentence by sentence. Then we had a native
English speaker read and edit the whole manuscript. More-
over, we have added many computational details, which we
intentionally omitted from the original submission as we
felt with those details, the manuscript might look more like
a technological report. Obviously, we made the wrong
choice. We hope these revisions have improved the clarity of
our manuscript.
Quality of written English:
Not suitable for publication unless extensively edited.
Reviewer number: 2 Dr. Limsoon Wong, NUS, Singapore
This manuscript studies gene expression data of two
lung cancer subtypes. It specifically investigates whether
there are subtype-specific prognostic biomarkers. Using
the methodology proposed in the paper, no significant
biomarkers are found. The manuscript then concludes
the absence of such biomarkers.
I think this study is deficient in the following aspects:
1/ Prognosis depends on the treatment used. If the
treatment is up-stream of both the subtypes, the success
of the treatment may not be subtype dependent. If the
treatment is down-stream (i.e., subtype specific), its success
of course depends on the subtype. A subtype can only be
considered to have poor prognosis if there is no available
effective treatment for it. It seems that the authors have
not considered this aspect. So I think the results in the
paper have not been interpreted soundly and the conclu-
sion as made in the paper is not stated correctly.
Authors’ response: As we mentioned in the Back-
ground section, for both subtypes of NSCLC patients at
early stages, the surgical resection is the only effective
treatment. However, even among patients having the
surgery, half of them die of tumor recurrence. Although
subtype-specific downstream treatments are available,
their effectiveness is also very limited. Both AC and
SCC patients have poor survival rates, which motivates
us to identify gene expression prognostic markers for
risk stratification and potentially more personalized
medicine. As the tumor development mechanisms are
fundamentally different between two subtypes, we hy-
pothesized that there may exist prognostic genes that
are specific to a certain subtype. We then evaluated the
difference in prognostic value of a given gene for the
two subtypes by testing the interaction term between
gene expression and subtype in a Cox regression model.
Since no significant interaction was identified, we con-
cluded that there is no evidence to support the subtype-
specific gene expression prognostic markers. We have
emphasized this point specifically in the manuscript.
2/ The authors proposed an specific methodology to
identify subtype-specific prognostic genes. Even ignor-
ing issues raised in 1/, one can only conclude (i) the
inability of the proposed methodology to find such bio-
markers, rather than (ii) the absence of such bio-
markers. Moreover, the proposed approach is quite
simple minded and, I suspect, is not much better than
the common individual-gene-based approach studied in
e.g., Venet et al. (PLoS Computational Biology,
7(10):e1002240, 2011). So scenario (i) is more likely the
case. It does not rule out the possibility of more ad-
vanced methods, such as pathway-based analysis (e.g.
Bioinformatics, 30(2):189-196, 2014), may have a better
chance of finding such biomarkers.
Authors’ response: We agree with the reviewer that we
can only conclude (i) and not (ii). To clarify this point,
we 1) use the simulations to show the proposed procedure
can not identify the significant interaction terms (i.e., the
subtype-specific genes) when the signals of such terms are
weak or even moderate, and 2) present the limitations of
this study in the conclusions section and carefully choose
words like “no evidence of” rather than ” no existence or
absent of such biomarkers.”
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Our work here is one among the first efforts to explore
subtype-specific prognostic genes. Our proposed method is
“simple-minded”, which makes it easy for a biologist or
clinician to understand and interpret. Although the
method may not be statistically optimal, we hope it will
spark interest in this research area, and ultimately lead
to the development of more advanced methods and better
understanding of the prognostic value of gene expression
data for each NSCLC subtype.
3/ I find the description of the method a little hard
to comprehend in a single reading. Its presentation
needs to be improved to make it more readable for a
broader audience.
Authors’ response: We have edited the description of
the method extensively.
Quality of written English:
Needs some language corrections before being published.
Reviewer number: 3 Dr. Jun Yu, Chinese Academy of
Sciences, China
Report form:
Tian et al. proposes a simple filter-based feature selec-
tion algorithm in a Cox regression model to analyze
some real microarray data and found no evidence sup-
porting the existence of histology-specific prognostic
gene signature for early-stage AC and SCC samples. The
authors suggest a 31-gene prognostic gene signature in
addition to what were evaluated, such as 15-gene and
144-gene signatures. As it is nothing wrong to explore
better algorithms for gene expression analysis, my major
concerns here are several folds. First, microarray tech-
nology has is lethal weakness: poor in its dynamic range,
i.e., it cannot distinguish the difference among lowly-
expressed genes (in arrange of 1 to 10 copies per cell)
and highly expressed genes (say a few hundred copies
per cell). As a result, transcripts in a copy number range
of 0.1 to 10 are not easily included in the analysis, which
are most likely filtered out as noise after normalization.
Second, genes are regulated at different levels so that
they need to be further stratified for any in-depth ana-
lysis in terms of tissue-specificity and functional rele-
vance (for an example, please see: Chen et al. [32]).
Third, normal expression controls are of essence for the
identification of gene expression differences. For in-
stance, the altered expression of a gene in a tumor tissue
is only relevant to its original normal expression vari-
ability. Furthermore, an altered expression may also be
related to its variability as its normal expression may
have a very broad range. I would like to see some
additional analyses and discussions based on these
principles.
Authors’ response: We thank the reviewer for his fair
comments. Here we address the points he raised one by one.
1) We think that the weakness of microarray technol-
ogy in its limited dynamic range can be regarded as
one limitation of this study. To address this issue, we
investigated experiments conducted on RNA-seq, which
has a much better dynamic range. Specifically, we
downloaded RNA-seq data from the Cancer Genome
Atlas (https://tcga-data.nci.nih.gov/tcga/) and applied
our proposed procedure. We still failed to identify any
subtype-specific prognostic signatures. We have added a
discussion of the analysis using the RNA-seq data to the
Results section.
2) Further stratification for any in-depth analysis in
terms of tissue-specificity and functional relevance is an
interesting topic that we would like to explore in the
future. In this study, our major objective is to introduce
the method/procedure we proposed to test the research
hypothesis on the existence of NSCLC subtype-specific
prognostic genes. It represents our first strategy to tackle
this problem. More in-depth analysis will be part of
future research. We have added one paragraph on the fu-
ture work and indicated some improvement we can make
on this method to the Conclusion section.
3) We agree with the reviewer that inclusion of normal
controls might help to identify subtype-specific prognostic
markers. Therefore, we did such analysis using the RNA-
seq data from TCGA project. The results have been
added to the Results section. Nevertheless, we also re-
mark that we are more interested in a direct comparison
between SCC and AC samples, aiming to explore if there
are some unique prognostic markers for each subtype
given that it is not common practice in the clinical set-
ting to have normal controls.
The tables need notes and the figure legends need to
be more detailed.
Authors’ response: Done.
As a final note, the manuscript requires intensive edit-
ing for clarity and grammar. The authors should try to
reduce the length of some long sentences so the readers
would have chance to understand them in one read-
through. Ten of the grammatical errors and unclear sen-
tences/phrases are listed as an example (randomly re-
corded from the text; possible errors are highlighted
with underscore):
1. “that a proportion of stage I subjects have poorer
prognosis”
2. “identification of poor prognosis of early stage
NSCLC patients will assist in the prescription and
administration of additional therapeutic
intervention, which (identification or intervention?)
potentially leads to better survival for those patients”
3. “Microarray technology allows simultaneous
monitoring and measuring of tens of thousands of
gene expression”
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4. “When analyzing (who?) data from a microarray
experiment, a feature selection algorithm is usually
considered to tackle with difficulties associated with
the problem of the number of covariates being
much larger compared with to the number of
samples, and to define a relevant gene subset
informative about the underlying differences among
different phenotypes”.
5. “a feature selection algorithm can be categorized
into three types”
6. “penalty instead and claim (that) the proposed
method has better stability, saves computing time,
and achieves the global optimum”
7. “there exists fundamental differences”
8. “In addition, the expression barcode values [15,16]
instead of the actual expression values are proposed
to be used, which eliminates genes with weak
association”.
9. “that demonstrated a certain degree of variation
across samples in each study were selected”.
10. “we hypothesized that there might exist some
specific genes relevant to survival rates uniquely for
each of these two histology subtypes”
Authors’ response: Thanks for highlighting these sen-
tences for illustration. We have made extensive edits to
our writing.
Quality of written English:
Not suitable for publication unless extensively edited.
Round 2
Reviewer 1
As a result of extensive editing, the exposition quality of
the paper has improved substantially and its content has
now become more transparent. However, I still have
many reservations about the study’s set-up, method-
ology, and results.
1. I believe the paper confuses biological aggressive-
ness of the types of cancer under study and clinical
prognosis. While it can be hypothesized that the former
depends on genes the latter depends critically on many
non-genetic variables (smoking status, family history of
lung cancer, tumor grade, tumor size and localization,
type of treatment etc.). Any sound genomic study should
control for these important non-genetic variables.
Authors’ response: We agree with the reviewer that
clinical prognosis may depend on many non-genetic vari-
ables. Even though the study population in this micro-
array study is relatively homogenous (at early stages and
adjuvant treatments naïve given it has been collected for
validation on the 15-gene prognostic signatures), we have
added one extra model using selected genes and some
clinical variables as covariates to get a better control for
those clinical factors.
2. Adenocarcinoma and squamous cell carcinoma origin-
ate from very different cell types. I think before analyzing
gene expression profiles of cancer cells it would be useful
to study gene expressions of their normal counterparts.
Authors’ response: As suggested by reviewer 3 in the
first round of revisions, we indeed included some normal
controls in our add-on RNA-seq analysis. In that ana-
lysis, we did found some potential subtype-specific prog-
nostic genes. The details on this analysis are presented in
the Results section.
Nevertheless, given the fact that it is not common prac-
tice in the clinical setting to have normal controls we still
believe a direct comparison between SCC and AC sub-
types is of practical importance.
3. Gene expression signatures obtained in the work re-
sulted from a somewhat obscure maze of statistical ma-
nipulations with ad hoc selected parameters. But what is
the general definition of genetic signature the authors
are looking for? What extremal properties does it have?
Authors’ response: By identifying a genetic signature, in
general, we mean to select genes whose expression values
are associated with the outcome. Those selected genes, inde-
pendent of clinical markers, may provide insightful infor-
mation on the phenotype under consideration.
We are not sure about what “extremal” means. If it
means “asymptotic”, a resulting signature from a fea-
ture selection algorithm should ideally be able to iden-
tify the true predictors who are associated with the
outcome and exclude the irrelevant ones, and the esti-
mators for the coefficients of those relevant predictors
are consistent (they converge in probability to their true
values when the sample size tends to infinite).
4. Given that the results of the article have consistency
problems both internally and when compared with other
studies and that the study with synthetic data also leads
to unexpected results, one may suspect that the method
employed is problematic. The ultimate test for validity
of any method is its predictive power. I suggest that the
method be tested against real gene expression data
where the presence of stable gene expression signatures
was firmly established.
Authors’ response: We agree with the reviewer that the
predictive power is ultimately important and acknow-
ledge him for this insightful comment. We reran the ana-
lysis without using 5-year censoring (the change we made
to address question 8 in the following page) and com-
pared the resulting prognostic signature with two other
existing prognostic signatures and signatures constructed
using novel algorithms. It turns out that our method
has good predictive power based on the considered pre-
dictive statistics.
Previously, we considered seriously to test our method
on a real data where the presence of stable gene expres-
sion signatures was firmly established when we set up the
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manuscript. Nevertheless, we found that it is impossible
to implement empirically. There are many gene expres-
sion data on cancers, but we cannot find a cancer data
where a stable prognostic signature was firmly estab-
lished, let alone those diseases are less studied than can-
cers using gene expression profiles.
5. Statistical methods employed depend on many as-
sumptions. For example, for T-test to be applicable, nor-
malized and log-transformed raw expression signals
should be i.i.d. and normally distributed. Is this even
remotely the case? Also, for Cox model to work, hazard
functions for different patients should be proportional.
Are they?
Authors’ response: Moderated T-tests used to filter
the DEGs were conducted using limma package in R
Bioconductor project. The functions in Limma have
considerable good toleration to mild or moderation de-
viation from the normality assumption and moderated
t-test is the most commonly used method to identify
DEGs. Also, given in both microarray and RNA-seq
data, the sample sizes for both histology subtypes are
big enough for CLT to be applicable, we have no worry
about the validness of moderated t-tests for filtering
out non-DEGs.
For the Cox model filter, Schoenfeld residuals for those
models were assessed to ensure the proportionality as-
sumption was met.
6. Statistical models for data are useful only if they fit
the data well enough. No evidence for the goodness-of-
fit or analysis of residuals was presented.
Authors’ response: For the final model, we have con-
ducted goodness-of-fit test to show this model fits well
enough. One sentence describing of this analysis has been
added to the Results section.
7. I understand what hazard function for a patient is.
What is it for a gene and for a gene-patient pair?
Authors’ response: In this article, we consider hazard
function for a patient using her/his gene expression value as
a covariate. First, we considered each gene individually to
filter statistically significant ones. Then, we fitted a Cox
model with all selected gene expression as covariates to
compute the risk score for each patient.
8. In the case of early-stage NSCLC, selection of 5 years
as a cut-off for censoring seems to be a poor choice. Ac-
cording to SEER data, 5-year survival for NSCLC patients
diagnosed in 1998-2000 was 49%, 45%, 30% and 31% for
stages IA, IB, IIA and IIB, respectively. Thus, censoring at
5 years significantly reduces statistical power of the analysis.
Authors’ response: We highly appreciate the reviewer
for this insightful comment. We have reanalyzed micro-
array without cutting off at 5-year and found out huge
difference takes place without censoring at 5 years. The
whole manuscript has been redone consequently. It is
because for the microarray data, about half of patients
had been followed up more than 5 years, and thus
censoring at 5 years does significantly reduce statistical
power of the analysis.
9.In the Barcode algorithm, why instead of using un-
testable distributional prior assumptions on mu_g and
tau_g one cannot estimate them from the data
nonparametrically?
Authors’ response: For the barcode algorithm, there
are two relevant subsequent versions. Specifically, in the
first version mu_g (the first peak in empirical density
curve for each gene) and tau_g (expression values to the
left of this first mode were used to get the estimate) are
estimated non-parametrically. Since this version requires
genes to show clear separation between low and high ex-
pression values in order to classify silenced and expressed
groups, they choose to use EM algorithm to estimate
those parameters with those distributional prior assump-
tions in the second version. Thus complete expression
barcode calls for all genes on the array are possible.
For barcode 2.0, they have extended search over the GEO
and ArrayExpress repositories to include all eligible samples
(e.g., for Hgu133plus2 platform there are 18,656 samples).
The resulting estimates on those parameters are deposited
into an R Bioconductor package. So far, barcode 2.0 has
been applied to a number of real-world data and demon-
strated to have considerable good performance. Even though
the authors have not provided any justification on these
assumptions, these are the most commonly used ones for
mean and variance in Bayesian inference.
10. The authors stated without showing data that
their results are consistent for different cut-off thresh-
olds, significance levels, etc. What are these “results”?
It would be good to present, for example, the number
of genes surviving filtering as a function of these tun-
ing parameters and other sensitivity curves.
Authors’ response: we have made figures showing how
the number of genes surviving filtering and performance
statistics changed as a function of tuning parameters,
which was presented in Figure 4.
11. How was the performance of the authors’ algorithm
compared to other published studies?
Authors’ response: So far we have compared the result-
ing prognostic signature to other two relevant signatures,
showing the performance of our signature is comparable
to that of these signatures. In addition, we have added a
comparison between our proposed method and two state-
of-art algorithms to the manuscript.
12. The article still has many stylistic deficiencies that
are too numerous to list.
Authors’ response: we have made more extensive edi-
tions on the manuscript, aiming to identify and thus
eliminate those deficiencies as best as we can.
Quality of written English:
Needs some language corrections before being published.
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Reviewer 2:
1/ The work presented in this paper, at best, shows the
proposed method fails to find prognostic markers for
certain lung carcinoma. I do not consider this to be in-
teresting or important.
Authors’ response: We reanalyzed the data without
censoring the survival time at 5-year, as suggested by
Reviewer 1, we found out the proposed method identifies
some subtype-specific prognostic markers for AC and
SCC lung carcinoma. The whole manuscript has been re-
done accordingly.
2/ Moreover, the failure of one method (which I doubt is
anywhere near the best) is far from sufficient to justify the
grand title “No evidence of …”. I expect many of the best
methods to be tried. This was not done. So the paper way
over claims its importance and misleads by its title.
Authors’ response: Thanks for pointing this out. We
must have miscomprehended the meaning of “No evi-
dence of…”. To fix this, we have renamed this manuscript
to provide a better outline on what the focus of this
manuscript is.
Based on the experience from svb IMPROVER chal-
lenge, Tarca et al. [33] concluded there is no such thing
as an optimal method that is uniformly superior for all
data. Applying to suitable data, a simple-headed method
like t-test based filter can outperform many complicated
feature selection algorithm, as shown by Haury et al.
[34]. We are confident about the soundness of our pro-
posed method. Especially after lifting the 5-year censoring
cutoff, the proposed method identified some subtype-
specific genes and those genes behold good performance.
3/ In the authors’ response letter, it is stated that the only
successful treatment is surgical resection and that this still
has 50% relapse. A reasonable postulate of the relapse is
that the tissue immediately surrounding the surgery site
contains some “seeds” for the carcinoma. Thus the relapse
would be determined by whether this surrounding tissue
contains such seeds, rather than by the (gene expression)
profile tissue that was resected. Then, in this case, the
method and experiments proposed by this paper (for iden-
tifying prognostic markers) does not make very strong
sense to me. It may be more reasonable to profile the sur-
rounding tissue of the site instead.
Authors’ response: The word “only” should be “most”,
sorry for this mistake. Studies have recently shown that
survival of early stage NSCLC patients can be improved
with adjuvant chemotherapy. Therefore, researchers have
began to seek genetic prognostic markers, which may be pre-
dictive of survival benefit from such therapy and thus be
guide of personalized medicine to improve their survival.
Additionally, as we understand surgeons usually resect
some adjacent normal tissues in order to eliminate those
“seeds” for the carcinoma when they perform the surgery.
Based on these and gene expression profile in primary
tumor may be also a good indicator on how invasive
tumor cells are, we believe it is reasonable to explore on
the prognostic gene markers.
4/ The abstract claims a 31-gene prognostic signature.
This contradicts the conclusion that there is no prog-
nostic signature. This is very confusing.
Authors’ response: Sorry for the confusion. Actually
there is no contradiction at all. The 31-gene prognostic
signature is for the one in common for both SCC and AC
subtypes. Our conclusion is that we cannot find histology
subtype specific prognostic signature, which does not
imply there is no common prognostic genes for those two
subtypes. To eliminate the possibility of such confusion
may arise again, we have revised the wording in the cor-
responding sentences to clarify what kind of signatures
they are.
Notably, without cutoff at 5-year the results are to-
tally different. But we still have explicitly differed the
concepts of subtype-specific and general (common) in
both subtypes.
5/ Also, the paper appears to try to “sell” the proposed
method for finding prognostic markers. If this is the pur-
pose, the authors should compare it to other state-of-the-
art methods and clearly prove its superiority in terms of
generality, reproducibility, etc.
Authors’ response: The proposed method is, to our best
knowledge, one of its kinds so far. However, given we are
trying to show a method specifically for finding histology-
subtype unique prognostic makers indeed, we have ap-
plied some methods separately to SCC and AC samples,
identified the corresponding signatures and compared
their performance with that of our proposed method. The
results have been added to the manuscript.
Overall, I do not know what the focus of the paper
is. If it is to show the non-existence of prognostic
markers for the lung carcinomas considered, it has
failed to so do convincingly. If it is to show that the
proposed method is good, it has failed to demonstrate
its superiority against current state of the art. If it is
just to show that the proposed method cannot find any
prognostic markers for the carcinomas considered, I
do not see why it is interesting. I am inclined on
rejecting the paper.
Authors’ response: We hypothesize that there is separ-
ate set of prognostic genes that are different among SCC
and AC lung carcinomas. To test on this research hy-
pothesis, we propose a feature selection algorithm using
the Cox-model in Equation 1 as a filter.
To further clarify our work, we have elucidated the ob-
jectives more explicitly in the Introduction section and
added more analysis (including a comparison between
our proposed algorithm and other two state-of-the art
methods). We hope with these modifications, the manu-
script becomes eye-catching.
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Quality of written English:
Needs some language corrections before being published.
Reviewer 3:
The authors have revised the manuscript and addressed
some of the issues raised by the reviewers, included some
new data and performed additional analyses. Its English
has improved but still have room to do better. For instance,
the current title denies categorily the existence of subtype-
specific prognostic signatures, and it appears unnecessary.
The possibility actually still exists in the future when novel
methods allow better data acquisition and analysis.
Quality of written English:
Needs some language corrections before being published
Authors’ response: Thanks a lot for pointing this out,
the title is obsolete given we have conducted extra ana-
lysis and modified throughout the whole manuscript.
Therefore, we have changed the title to “Test on existence
of histology subtype-specific prognostic signatures among
early stage lung adenocarcinoma and squamous cell car-
cinoma patients using a Cox-model based filter” to out-
line and summarize our manuscript better.
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